EDUARD TEIXIDOR VILA

Projectes

Metabolisme i Càncer

Ayuda de personal Río Hortega 2022 - Eduard Teixidor

Codi oficial: CM22/00276 Data inici: 01/01/2023 Data fi: 31/12/2024 Investigador/a principal: JAVIER ABEL MENÉNDEZ MENÉNDEZ Organisme finançador: INSTITUTO DE SALUD CARLOS III

Metabolisme i Càncer

Estudio descriptivo y efecto del ritmo circadiano en el tratamiento con quimio-inmunoterapia neoadyuvante del cáncer del pulmón de célula no pequeña en estadios precoces. Un estudio multicéntrico con resultados de Real World Data (RWD)

Codi oficial: 2024_GECP_CMF Data inici: 03/10/2024 Data fi: 02/10/2026 Investigador/a principal: CLAUDIA MONTAÑES FERRER Organisme finançador: GRUPO ESPAÑOL DE CANCER DE PULMON

Publicacions

Metabolisme i Càncer , Oncologia de Precisió de Girona

Verdura S, Encinar JA, Gratchev A, Llop-Hernández À, López J, Serrano-Hervás E, Teixidor E, López-Bonet E, Martin-Castillo B, Micol V, Bosch-Barrera J, Cuyàs E, Menendez JA

Silibinin is a suppressor of the metastasis-promoting transcription factor ID3

Phytomedicine, 2024, 128, 155493-155493 dx.doi.org/10.1016/j.phymed.2024.155493

Oncologia de Precisió de Girona , Malalties Digestives i Microbiota

Sabaté-Ortega, J, Albert-Carrasco, M, Escribano-Ferrer, C, Grau-Manrubia, G, Fina-Planas, C, López-Núnez, C, Teixidor-Vilà, E, Bujons-Buscarons, E, Montañés-Ferrer, C, Sala-González, N

Case report: Uncommon gastric metastasis as a presentation of recurrent clear cell renal cell carcinoma

Frontiers in oncology, 2024, 14 dx.doi.org/10.3389/fonc.2024.1354127

Metabolisme i Càncer , Oncologia de Precisió de Girona

Cuyàs E, Pedarra S, Verdura S, Pardo MA, Espin Garcia R, Serrano-Hervás E, Llop-Hernández À, Teixidor E, Bosch-Barrera J, López-Bonet E, Martin-Castillo B, Lupu R, Pujana MA, Sardanyès J, Alarcón T, Menendez JA

Fatty acid synthase (FASN) is a tumor-cell-intrinsic metabolic checkpoint restricting T-cell immunity.

Cell Death Discovery, 2024, 10, 417-417 dx.doi.org/10.1038/s41420-024-02184-z

Oncologia de Precisió de Girona , Metabolisme i Càncer

Teixidor E, Sais E, Vásquez CA, Carbajal W, Hernández A, Sánchez G, Izquierdo A, Verdura S, Menéndez JA, Bosch-Barrera J

Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma.

Oncotarget, 2023, 14, 668-668 dx.doi.org/10.18632/oncotarget.28471

Metabolisme i Càncer , Epidemiologia descriptiva, genètica i prevenció del càncer , Oncologia de Precisió de Girona

Bosch-Barrera J, Roqué A, Teixidor E, Carmona-Garcia MC, Arbusà A, Brunet J, Martin-Castillo B, Cuyàs E, Verdura S, Menendez JA

Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin

Pharmaceuticals, 2022, 15 dx.doi.org/10.3390/ph15010019

Metabolisme i Càncer , Oncologia de Precisió de Girona

Monteiro C, Miarka L, Perea-García M, Priego N, García-Gómez P, Álvaro-Espinosa L, de Pablos-Aragoneses A, Yebra N, Retana D, Baena P, Fustero-Torre C, Graña-Castro O, Troulé K, Caleiras E, Tezanos P, Muela P, Cintado E, Trejo JL, Sepúlveda JM, González-León P, Jiménez-Roldán L, Moreno LM, Esteban O, Pérez-Núñez Á, Hernández-Lain A, Mazarico Gallego J, Ferrer I, Suárez R, Garrido-Martín EM, Paz-Ares L, Dalmasso C, Cohen-Jonathan Moyal E, Siegfried A, Hegarty A, Keelan S, Varešlija D, Young LS, Mohme M, Goy Y, Wikman H, Fernández-Alén J, Blasco G, Alcázar L, Cabañuz C, Grivennikov SI, Ianus A, Shemesh N, Faria CC, Lee R, Lorigan P, Le Rhun E, Weller M, Soffietti R, Bertero L, Ricardi U, Bosch-Barrera J, Sais E, Teixidor E, Hernández-Martínez A, Calvo A, Aristu J, Martin SM, Gonzalez A, Adler O, Erez N, RENACER, Valiente M

Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism

NATURE MEDICINE, 2022, 28, 752-765 dx.doi.org/10.1038/s41591-022-01749-8

Oncologia de Precisió de Girona , Metabolisme i Càncer

Verdura S, Encinar JA, Teixidor E, Segura-Carretero A, Micol V, Cuyàs E, Bosch-Barrera J, Menendez JA

Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors

Cancers, 2022, 14 dx.doi.org/10.3390/cancers14246101

Metabolisme i Càncer , Oncologia de Precisió de Girona

Teixidor E, Bosch-Barrera J

The dark side of immunotherapy: challenges facing the new hope in cancer treatment

Annals of Translational Medicine, 2019, 7 dx.doi.org/10.21037/atm.2019.07.69

Metabolisme i Càncer , Epidemiologia descriptiva, genètica i prevenció del càncer , Oncologia de Precisió de Girona

Teixidor E, Sais E, Vásquez CA, Carbajal W, Hernández A, Sánchez G, Izquierdo A, Verdura S, Menéndez JA, Bosch-Barrera J

Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma.

Oncotarget, 2018, 9, 33043-33049 dx.doi.org/10.18632/oncotarget.25984

Directori

Projectes

Publicacions

Silibinin is a suppressor of the metastasis-promoting transcription factor ID3

Case report: Uncommon gastric metastasis as a presentation of recurrent clear cell renal cell carcinoma

Fatty acid synthase (FASN) is a tumor-cell-intrinsic metabolic checkpoint restricting T-cell immunity.

Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma.

Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin

Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism

Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors

The dark side of immunotherapy: challenges facing the new hope in cancer treatment

Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma.

Formulari de contacte

Coneix l’IDIBGI!